Our technological research platform VirNext is very pleased to be alongside the spin-off VirexpR in this strategic initiative in the Auvergne-Rhône-Alpes region, which aims to contribute to a better Indoor Air Quality.


This consortium is part of the partnership dynamic that we initiated in November 2020 with the Auvergne-Rhône-Alpes Region, the Lyonbiopôle competitiveness cluster and the company VirHealth by implementing the first studies in Europe to evaluate in a test chamber the performance of several air treatment devices in an atmosphere contaminated by the infectious SARS-CoV-2 virus. On the basis of the experimental results obtained and previous technical knowledge of these devices, the Auvergne-Rhône-Alpes Region had released a budget of 10 million euros to install 2,500 air purifiers in 285 high schools and 189 municipalities in the territory to strengthen measures limiting the spread of the SARS-CoV-2 virus in the population.


We are proud to contribute with our partners VirexpR, CONIDIA CONIPHY and IMeBIO of the GESPPAIR consortium, the TERA Group and the companies ASPIDA and AIRXOM to a better control of emerging and re-emerging respiratory viral pathogens and more globally to a better IAQ of confined environments. This GESPPAIR alliance also illustrates our intention to create technological, economic and societal values in the Auvergne-Rhône-Alpes region and to contribute to the development of French industries and their international competitiveness.

VirNext offers preclinical models of infection with several SARS-CoV-2 variants in order to evaluate prophylactic and therapeutic candidates.

VirNext provides expertise in the field of respiratory viruses (influenza, pneumoviruses, adenovirus, rhinovirus, coronaviruses and all SARS-CoV-2 variants of interest) and a large panel of technologies including egg and cell-based process of virus and vaccine antigen production, and several in vitro and in vivo preclinical models of infection.


Here under is a reconstructed human airway epithelium MucilAir (Epithelix) infected by the SARS-CoV-2 B.1.617.2 Delta strain observed by confocal microscopy at CIQLE (Centre d'Imagerie Quantitative Lyon Est) Université Claude Bernard Lyon 1. Nuclei are blue, SARS-CoV-2 Spike staining is red and cell membranes are green.


#infectiousdiseases #virus #coronavirus #SARSCOV2 #Covid19 #antivirals #microscopy


VirexPR has inaugurated its new 20 m3 test bench.


Our technological research platform VirNext is very proud of the spin-off VirexpR which has just reached a major step in its technological and strategic development plan.


Thanks to its partner ASPIDA for the joint design and realization of this unique test bench in Europe which will allow VirexpR to position itself as an international reference in the management of microbiological and virological environmental pollution, and indoor air quality in confined spaces, whose health, economic and societal issues are major.





VirexpR is a good illustration of our commitment with the Claude Bernard Lyon 1 University and its subsidiaries EZUS and Lyon Ingénierie Projet, with the strong support of the Auvergne-Rhône-Alpes Region, to transfer scientific and technological innovation from our research laboratory to the industry in order to develop and implement new methods of protection against respiratory viral infections, while creating economic and societal value.


We would also like to thank Mr. Mickaël PACCAUD, Regional Councillor and Mrs. Nathalie MEZUREUX, Regional Academic Delegate for Research and Innovation in Auvergne-Rhône-Alpes, as well as the TERA Group, ASPIDA IMeBIO, CONIDIA CONIPHY Bpifrance Auvergne-Rhône-Alpes Entreprises ANRT - National Association for Research and Technology AXELERA Lyonbiopôle for their support and their confidence in the laboratory and our technological research platform. 

Our collaborative study on the distinct effects of favipiravir in non-human primate (NHP) models of experimental infection by SARS-CoV-2 or Zika virus has been published in Nature Communications


Our results support considering the clinical evaluation of favipiravir against Zika virus but they advocate against its use against SARS-CoV-2 infection. Our models of SARS-CoV-2 infection in reconstituted Human Airway Epithelium (MucilAir) were predictive again of the results obtained in the cynomolgus NHP model, demonstrating that favipiravir, even at doses up to 600 μM, has no antiviral efficacy against SARS-CoV-2. 

Although our results are in contradiction with those obtained in Vero cell lines and hamster models of SARS-CoV-2 infection, they are consistent with the lack of antiviral activity of favipiravir recently reported in randomized clinical trials. This discrepancy clearly highlights the need for a synergistic setup of a pipeline of multiple predictive in vitro and in vivo preclinical models for the robust evaluation of future new antiviral candidates that will maximize their successful implementation in clinical trials.


Conducted by IDMIT, this study was possible thanks to a collaborative network among groups from CEA, l'Inserm, le CNRS - Centre national de la recherche scientifique, l'Institut Pasteur, l’Université de Paris-Saclay, IRD, APHM (Assistance Publique - Hopitaux de Marseille) and Aix-Marseille Université.


The contribution of our team VirPath and its Technology Research Platform VirNext  was supported by Inserm, CNRS - Centre national de la recherche scientifique @INSB CNRS Virocrib and INSTITUT MÉRIEUX.


CYNBIOSE and VirNext strenghten their public-private partnership to accelerate the development of innovative prophylactic and therapeutic treatments in the field of respiratory infections


Cynbiose and VirNext have joined forces to offer a unique and innovative preclinical package of services for the evaluation of drugs, vaccines and antibodies candidates against (re)-emergent respiratory viruses, from in vitro screening to in vivo efficacy models of infections, including large animals. On the basis of a public-private partnership initiated in 2017, we have contributed to the evaluation of hundreds of candidates for respiratory viruses, including SARSCoV2 variants, cell lines, reconstructed human respiratory epithelium (MucilAir, Epithelix) and in vivo models of infections, but also to the implementation of six clinical trials evaluating antivirals, nebulized antibodies and vaccine candidates.

VirNext and Cynbiose are in the front line in meeting the ambitions of France2030innovation plan and actively contributing to strengthening the international positioning of the #BioclusterLyon, Région Auvergne-Rhône-Alpes and France in the fight against (re)-emerging infectious diseases. We are proud to support academic teams and the biopharmaceutical industry with a very high value-added scientific and technical offer to speed up entry to the clinics of drug candidates (immunotherapies, vaccines, antibodies, antivirals) and thus contribute to #globalhealth.

VirNext a remporté le prix de l'innovation 2021 au salon Contaminexpo.


VirNext est très fière d'être lauréate du prix de l'innovation 2021 #Contaminexpo remis par Bastien Cany et Stéphane ORTU. Nous remercions l'Aspec Association, Salles Propres et les membres du jury pour leur confiance et la reconnaissance de nos savoir-faire dans la génération d'atmosphères hautement contaminées par des virus respiratoires, incluant le #SARSCOV2, dédiés à l'évaluation des technologies et dispositifs épurateur d'air.

Un grand merci à toutes les équipes de l'Aspec Association pour l'organisation de ce salon très prolifique en interactions avec de nombreux professionnels de la qualité de l'air intérieur.

VirNext a participé au Salon POLLUTEC


Notre plateforme VirNext était présente du 12 au 15 octobre au salon #Pollutec à Lyon Eurexpo afin d’échanger sur nos savoir-faire uniques dans l’évaluation des technologies de purification de l’air contre le virus SARS-CoV-2 et autres virus respiratoires pathogènes.

Méthodologie expérimentale d'évaluation de performance d'épurateurs d'air contre le SARS-CoV-2 en banc d'essais de grand volume.


Notre plateforme VirNext est toujours mobilisée dans la lutte contre la Covid-19 en évaluant expérimentalement différentes technologies de purification de l’air en partenariat avec Lyonbiopôle #CentreInnovation et dans la dynamique insufflée par la Région Auvergne-Rhône-Alpes.


VirNext présentera ses expertises et services pour l’évaluation de performance des technologies de décontamination de l’air intérieur contre les virus respiratoires au salon #ContaminExpo, le rendez-vous incontournable des acteurs de la maîtrise de la contamination et des salles propres (12 au 14 octobre 2021 à Paris, Porte de Versailles).


VirNext sera également présente au salon #Pollutec du 12 au 15 octobre 2021 à EUREXPO LYON dans le Hall de la qualité de l’air.

Evaluation de performance de purificateurs d’air contre le SARS-CoV-2 et la persistance de ce virus sur filtre HEPA


Notre plateforme de recherche technologique #VirNext est très fière d'avoir remis à M Laurent Wauquiez, Président de la Région Auvergne-Rhône-Alpes les conclusions de l’étude menée avec la société #VirHealth et le support de Lyonbiopôle #CentreInnovation sur l’évaluation de performance de purificateurs d’air contre le SARS-CoV-2 et la persistance de ce virus sur filtre HEPA.


La mise en synergie de nos savoir-faire sur les virus respiratoires et des équipements de notre laboratoire #VirPath  et de notre plateforme de recherche technologique Université Claude Bernard Lyon 1 avec l’expertise et la logistique de la société #VirHealth, spécialisée dans l’évaluation des activités virucides des produits, équipements et technologies de désinfection, et le support de Lyonbiopôle #CentreInnovation, nous a permis de répondre dans l’urgence au défi technologique de la Région Auvergne-Rhône-Alpes. Cela illustre le dynamisme de notre écosystème et la compétitivité que peuvent avoir de tels partenariats de recherche « public-privé », en termes de création de valeurs scientifiques, technologiques, économiques et sociétales. 

CP LBP - VirPath Virhealth Région .pdf
Adobe Acrobat Document 663.8 KB
Adobe Acrobat Document 614.7 KB

Launch of Cynbiome network


We are pleased to announce the launch of Cynbiome, a preclinical excellence network on microbiome and infectious diseases. We congratulate the principal investigator Cynbiose, a service company specializing in the development and commercialization of innovative preclinical models.


CYNBIOME is financed by the French government and the Auvergne- Rhône-Alpes region and is supported by The French Public Bank of Investment (Bpifrance).


Our Technological Research Platform VirNext are very proud to be partners of the cynbiome network. We will bring our expertises, OMICS analytic tools and biological materials in the field of infectious diseases to contribute in the development of this ambitious and unique network in EU.

Presence on Linkedin


Now, you can follow the page "VirNext" on Linkedin. You will find news, shares and likes of the platform.